Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020135318 - APPLICATION OF CD38 INHIBITOR IN PREPARATION OF ANTI-RHEUMATOID ARTHRITIS DRUG

Publication Number WO/2020/135318
Publication Date 02.07.2020
International Application No. PCT/CN2019/127369
International Filing Date 23.12.2019
IPC
A61K 45/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A61P 29/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
A61P 19/02 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
02for joint disorders, e.g. arthritis, arthrosis
G01N 33/569 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
G01N 33/68 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
CPC
A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
A61P 19/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
02for joint disorders, e.g. arthritis, arthrosis
A61P 29/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
G01N 2800/102
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
10Musculoskeletal or connective tissue disorders
101Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
102Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
G01N 33/56966
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
56966Animal cells
Applicants
  • 湖北添英生物医药科技有限公司 HUBEI ATALENT BIOPHARMA TECHNOLOGY CO., LTD [CN]/[CN]
Inventors
  • 常晓天 CHANG, Xiaotian
Agents
  • 南京纵横知识产权代理有限公司 NANJING ZONGHENG INTELLECTUAL PROPERTY AGENCY CO., LTD.
Priority Data
201811636987.029.12.2018CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) APPLICATION OF CD38 INHIBITOR IN PREPARATION OF ANTI-RHEUMATOID ARTHRITIS DRUG
(FR) APPLICATION D'UN INHIBITEUR DE CD38 À LA PRÉPARATION D'UN MÉDICAMENTS POUR LA POLYARTHRITE RHUMATOÏDE
(ZH) CD38抑制剂在制备抗类风湿关节炎药物中的应用
Abstract
(EN)
Provided is an application of a CD38 inhibitor in the preparation of an anti-rheumatoid arthritis (RA) drug. Studies have shown that the CD38+NK cell content and the ratio of CD38+NK / CD38+NKT in the blood and synovial fluid of an RA patient are increased, and such change is positively correlated with the DAS28 of the patient, indicating that CD38+NK cells and CD38+NKT cells are expected to become the therapeutic target of RA. Further research clearly shows that high levels of CD38+NK and a high ratio of CD38+NK / CD38+NKT in RA can reduce TGF-β secretion and activate the mTOR pathway of CD4+T cells in MNC, inhibiting the differentiation of CD4+T cells to differentiate Treg cells and IL-10 expression, increase the level of IFN-γ and the ratios of Thl/Th2 and Thl7/Treg, resulting in reduced anti-inflammatory and immune tolerance and exacerbating the course of RA.
(FR)
L'invention prote sur l'application d'un inhibiteur de CD38 à la préparation d'un médicament pour la polyarthrite rhumatoïde (RA). Des études ont montré que la teneur en cellules CD38+NK et le rapport CD38+NK / CD38+NK dans le sang et le liquide synovial d'un patient atteint de RA sont augmentés, et qu'une telle modification est corrélée positivement avec le DAS28 du patient, indiquant que les cellules CD38+NK et CD38+NKT devraient devenir la cible thérapeutique de la RA. D'autres recherches montrent clairement que des niveaux élevés de CD38+NK et un rapport élevé de CD38+NK/CD38+NKT dans la RA peuvent réduire la sécrétion de TGF-β et activer la voie mTOR des cellules CD4+T dans le MNC, inhibant la différenciation des cellules CD4+T pour différencier les cellules Treg et l'expression dE l'IL-10, augmenter le niveau d'IFN-γ et les rapports Thl/Th2 et Thl7/Treg, entraînant une réduction de la tolérance anti-inflammatoire et immunitaire et exacerbant l'évolution de la RA.
(ZH)
提供了CD38抑制剂在制备抗类风湿关节炎药物中的应用。研究表明RA患者血液和滑液中CD38+NK细胞含量、CD38+NK/CD38+NKT比例升高,变化情况与患者DAS28呈正相关,启示了CD38+NK细胞、CD38+NKT细胞有望成为RA的治疗靶点。进一步研究表明,RA中高水平的CD38+NK及CD38+NK/CD38+NKT比值可以降低TGF-β分泌和激活MNC中CD4+T细胞mTOR通路,抑制CD4+T细胞分化Treg细胞及IL-10表达、提升IFN-γ水平和Thl/Th2、Thl7/Treg比值,导致抗炎和免疫耐受能力降低,加剧RA病程。
Also published as
Latest bibliographic data on file with the International Bureau